Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -45.94% is 61% above its 5-year average of -117.41%, near the high end of its 5-year range (-554.03%–-0.08%).
17.12% below its 12-month average of -39.23%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.77%.
RETURN ON ASSETS (ROA)
-45.94%
RETURN ON ASSETS (ROA) AVG TTM
-39.23%
RETURN ON ASSETS (ROA) AVG 3Y
-37.58%
RETURN ON ASSETS (ROA) AVG 5Y
-117.41%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-17.12%
CURRENT VS 3Y AVG
-22.25%
CURRENT VS 5Y AVG
+60.87%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 781 covered companies
CURRENT VS SECTOR MEDIAN
-46.45%
vs the sector median at left
MoonLake Immunotherapeutics
Market Cap
$938.92M
Return on Assets (ROA)
-45.94%
TTM Avg
-39.23%
3Y Avg
-37.58%
5Y Avg
-117.41%
Market Cap
$930.92M
Return on Assets (ROA)
-39.67%
TTM Avg
-22.62%
3Y Avg
-34.56%
5Y Avg
-34.56%
Market Cap
$950.17M
Return on Assets (ROA)
-30.07%
TTM Avg
-30.07%
3Y Avg
-30.07%
5Y Avg
-30.07%
Market Cap
$949.00M
Return on Assets (ROA)
-50.49%
TTM Avg
-30.32%
3Y Avg
-31.10%
5Y Avg
-27.11%
Market Cap
$919.80M
Return on Assets (ROA)
-55.10%
TTM Avg
-55.10%
3Y Avg
-55.10%
5Y Avg
-55.10%
Market Cap
$952.91M
Return on Assets (ROA)
-72.50%
TTM Avg
-45.97%
3Y Avg
-37.50%
5Y Avg
-37.52%
Market Cap
$915.31M
Return on Assets (ROA)
4.06%
TTM Avg
3.72%
3Y Avg
3.23%
5Y Avg
2.82%
Market Cap
$900.08M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$976.32M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $938.92M | -45.94% | -39.23% | -37.58% | -117.41% |
| CeriBell, Inc. (CBLL)vs › | $930.92M | -39.67% | -22.62% | -34.56% | -34.56% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $950.17M | -30.07% | -30.07% | -30.07% | -30.07% |
| Kura Oncology, Inc. (KURA)vs › | $949.00M | -50.49% | -30.32% | -31.10% | -27.11% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $919.80M | -55.10% | -55.10% | -55.10% | -55.10% |
| Savara Inc. (SVRA)vs › | $952.91M | -72.50% | -45.97% | -37.50% | -37.52% |
| HealthStream, Inc. (HSTM)vs › | $915.31M | 4.06% | 3.72% | 3.23% | 2.82% |
| Bioventus Inc. (BVS)vs › | $900.08M | 8.09% | -0.64% | -8.03% | -4.54% |
| Aktis Oncology, Inc. (AKTS)vs › | $976.32M | -13.12% | -18.77% | -18.48% | -18.48% |
| MeiraGTx Holdings plc (MGTX)vs › | $980.52M | 19.92% | -50.75% | -41.99% | -34.79% |
ROA
-45.9%
ROE
-61.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -53.56% |
| 2024-12-31 | -24.89% |
| 2023-12-31 | -6.84% |
| 2022-12-31 | -65.03% |
| 2021-12-31 | -554.03% |
| 2020-12-31 | -0.08% |
